R&D Programs and Progress
PsiOxus aims to be the world leading cancer gene therapy company, delivering medicines of value to patients with cancer.
We focus on discovering and developing innovative gene-based immuno-oncology treatments for solid tumors using our proprietary intravenously administered T-SIGn virus platform. Our portfolio of differentiated gene therapy products are delivered intravenously to act locally within the tumor.
Enadenotucirev is a clinical stage oncolytic virus therapeutic with broad potential to target solid tumor carcinomas. Delivery of enadenotucirev to tumors has been demonstrated in the clinic following intravenous administration, giving enadenotucirev the potential for systemic treatment of advanced cancers.
Tumor-Specific Immuno-Gene Therapy (T-SIGn) is a broad platform for gene therapy combinations. T-SIGn utilizes the enadenotucirev virus as a vector system for the delivery of therapeutic genes to cancer cells. This includes simultaneous delivery of combinations of genes from a single product which in turn direct tumor cells to locally produce biologic therapies. In effect, the T-SIGn viruses turn the tumor cells into “drug factories”. The results are biological anti-cancer therapeutics produced locally within the tumor microenvironment for the treatment of cancer.
The first T-SIGn virus in our portfolio is NG-348 which was licensed to Bristol-Myers Squibb in 2016 and achieved clinical trial application approval in 2017. T-SIGn products include clinical stage NG-350A (an antibody gene therapy); NG-641 (a bi-specific gene therapy); and additional preclinical programs. Research is ongoing to discover and develop additional novel T-SIGn gene therapies, including in collaboration with the Parker Institute for Cancer Immunotherapy.